高齢者の貧血の世界市場レポート 2025年

高齢者の貧血市場規模は今後数年で力強い成長が見込まれます。2029年にはCAGR9.3％で43億2,000万米ドルに成長する見込みです。予測期間中に予想される成長の原動力は、高齢化、慢性疾患の有病率の上昇、診断ツールの進歩、ヘルスケアに対する意識の向上、治療へのアクセスの改善です。この期間の主な動向には、AI主導の診断、ウェアラブル健康モニター、高度な血液分析ツール、遠隔医療統合、個別化医療ソリューションなどがあります。

高齢者人口の増加が高齢者貧血市場の成長を牽引すると予想されます。平均寿命の延長、出生率の低下、大規模コホートの高齢化など、世界人口の高齢化に伴い、65歳以上の高齢者の割合は着実に増加しています。この人口動態の変化は、高齢者の貧血の重大な原因である加齢関連疾患や慢性疾患の有病率の上昇につながります。栄養不足、慢性疾患、加齢の影響などの要因による高齢者の貧血症例の増加が、この病態の診断、管理、治療の需要に拍車をかけています。例えば、2024年7月、国家統計局（ONS）は、英国の65歳以上の人口が2021年の1,100万人から2022年には1,270万人に増加したと報告しました。この高齢者人口の増加が高齢者貧血市場の拡大を牽引しています。

高齢者貧血市場の主要企業は、治療プロセスを最適化し、患者の治療効果を高め、副作用を最小限に抑え、ヘルスケア全体の効率を向上させるため、技術革新、特に個別化治療に注力しています。個別化治療は、各患者の固有のニーズに合わせたものです。例えば、インドに本社を置くカディラ・ファーマシューティカルズは2024年3月、経口鉄剤に耐えられない患者の鉄欠乏性貧血治療を目的とした新しい鉄剤注射剤、レッドショットFCMを発表しました。この点滴製剤は、十分な鉄分を供給し、高い安全基準を維持します。Redshot FCMは高度なカルボキシマルトース鉄を使用し、鉄の送達と吸収を高めます。この開発は、個々の患者のニーズに合わせた治療法を開発することでヘルスケアを進歩させ、最終的に鉄欠乏性貧血患者の転帰を改善するというコミットメントを強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界高齢者の貧血PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の高齢者の貧血市場：成長率分析
• 世界の高齢者の貧血市場の実績：規模と成長, 2019-2024
• 世界の高齢者の貧血市場の予測：規模と成長, 2024-2029, 2034F
• 世界高齢者の貧血総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の高齢者の貧血市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 注射剤
• 世界の高齢者の貧血市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鉄サプリメント
• エリスロポエチンまたは赤血球刺激剤
• ビタミンB12サプリメント
• 葉酸サプリメント
• 世界の高齢者の貧血市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の高齢者の貧血市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の高齢者の貧血市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鉄サプリメント
• ビタミンB12サプリメント
• 葉酸錠
• 赤血球造血刺激因子製剤（ESA）錠
• 世界の高齢者の貧血市場、注射剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鉄剤注射
• ビタミンB12注射
• 赤血球造血刺激因子（ESA）注射
• 葉酸注射

第7章 地域別・国別分析

• 世界の高齢者の貧血市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の高齢者の貧血市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 高齢者の貧血市場：競合情勢
• 高齢者の貧血市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Amgen Inc
• Japan Tobacco Inc
• Fresenius Medical Care AG
• Teva Pharmaceutical Industries Ltd
• Sandoz International GmbH
• CSL Limted
• Daiichi Sankyo Company Limited
• Amag Pharmaceuticals
• Akebia Therapeutics Inc
• Pharmacosmos A/S
• Rockwell Medical Inc
• Bioage Labs Inc
• Shield Therapeutics Plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 高齢者の貧血市場2029：新たな機会を提供する国
• 高齢者の貧血市場2029：新たな機会を提供するセグメント
• 高齢者の貧血市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anemia in the elderly refers to a condition where the number of red blood cells (RBCs) or hemoglobin levels falls below the normal range, reducing the blood's ability to carry oxygen in older adults (typically those aged 65 and older). This condition is often caused by nutritional deficiencies, chronic illnesses, or age-related physiological changes.

The main products used to treat anemia in the elderly include tablets and injectables. Tablets are solid oral medications commonly prescribed for older adults with anemia. Treatment options include iron supplements, erythropoietin or erythrocyte-stimulating agents, vitamin B12 supplements, and folic acid supplements. These treatments can be administered orally or parenterally and are typically provided through hospital pharmacies, online pharmacies, and retail pharmacies.

The anemia in elderly market research report is one of a series of new reports from The Business Research Company that provides anemia in elderly market statistics, including anemia in elderly industry global market size, regional shares, competitors with a anemia in elderly market share, detailed anemia in elderly market segments, market trends and opportunities, and any further data you may need to thrive in the anemia in elderly industry. This anemia in elderly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anemia in elderly market size has grown strongly in recent years. It will grow from $2.75 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historical period can be attributed to factors such as nutritional deficiencies, chronic diseases, inflammation, bone marrow disorders, and blood loss.

The anemia in elderly market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%.The anticipated growth in the forecast period is driven by an aging population, a rising prevalence of chronic diseases, advancements in diagnostic tools, increased healthcare awareness, and better access to treatment. Key trends during this period include AI-driven diagnostics, wearable health monitors, advanced blood analysis tools, telehealth integration, and personalized medicine solutions.

The growing elderly population is expected to drive the growth of the anemia in the elderly market. As the global population ages, with increased life expectancy, declining birth rates, and the aging of large cohorts, the proportion of individuals aged 65 and older is steadily increasing. This demographic shift leads to a higher prevalence of age-related and chronic conditions, which are significant causes of anemia in older adults. The rise in cases of anemia among the elderly, due to factors such as nutritional deficiencies, chronic diseases, and the effects of aging, is fueling the demand for diagnosis, management, and treatment of the condition. For example, in July 2024, the Office for National Statistics (ONS) reported that the number of people aged 65 and older in the UK grew to 12.7 million in 2022 from 11 million in 2021. This growth in the elderly population is driving the expansion of the anemia in the elderly market.

Leading companies in the elderly anemia market are concentrating on technological innovations, particularly personalized treatments, to optimize the treatment process, enhance patient results, minimize side effects, and improve overall healthcare efficiency. Personalized treatments are tailored to the unique needs of each patient. For example, in March 2024, Cadila Pharmaceuticals, based in India, unveiled Redshot FCM, a new iron injection aimed at treating iron deficiency anemia in patients who cannot tolerate oral iron. This intravenous formulation provides sufficient iron and maintains a high safety standard. Redshot FCM utilizes an advanced Ferric Carboxymaltose formula to enhance iron delivery and absorption. This development highlights a commitment to advancing healthcare by creating therapies tailored to individual patient needs, ultimately leading to improved outcomes for those with iron deficiency anemia.

In August 2022, CSL Limited, an Australian biotechnology company, acquired Vifor Pharma AG, a Swiss pharmaceutical company specializing in treatments for iron deficiency, especially among elderly patients and those with chronic kidney disease (CKD). This acquisition strengthens CSL's leadership in the iron deficiency anemia market and expands its presence in addressing the needs of various patient populations, further propelling the growth of treatments for anemia in the elderly.

Major players in the anemia in elderly market are Johnson & Johnson, Roche Holding AG, Merck & Co Inc, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Japan Tobacco Inc, Fresenius Medical Care AG, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, CSL Limted, Daiichi Sankyo Company Limited, Amag Pharmaceuticals, Akebia Therapeutics Inc, Pharmacosmos A/S, Rockwell Medical Inc, Bioage Labs Inc, Shield Therapeutics Plc, MegaPro Biomedical Co Ltd.

North America was the largest region in the anemia in elderly market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anemia in elderly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anemia in elderly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anemia in elderly market consists of revenues earned by entities by providing services such as diagnostic testing, medical consultations and treatment plans, and administration of iron infusions or blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The anemia in elderly market also includes sales of iron supplements, vitamin B12, folic acid supplements, and diagnostic equipment such as hemoglobin meters and blood test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anemia In Elderly Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anemia in elderly market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anemia in elderly ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anemia in elderly market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Tablets, Injectable
• 2) By Treatment: Iron Supplements, Erythropoietin Or Erythrocyte-Stimulating Agents, Vitamin B12 Supplements, Folic Acid Supplements
• 3) By Route Of Administration: Oral, Parenteral
• 4) By End User: Hospital pharmacy, Online Pharmacy, Retail pharmacy
• Subsegments:
• 1) By Tablets: Iron Supplements; Vitamin B12 Supplements; Folic Acid Tablets; Erythropoiesis-Stimulating Agents (ESAs) Tablets
• 2) By Injectable: Iron Injections; Vitamin B12 Injections; Erythropoiesis-Stimulating Agents (ESAs) Injections; Folic Acid Injections
• Companies Mentioned: Johnson & Johnson; Roche Holding AG; Merck & Co Inc; Bristol-Myers Squibb Company; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anemia In Elderly Market Characteristics

3. Anemia In Elderly Market Trends And Strategies

4. Anemia In Elderly Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anemia In Elderly Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anemia In Elderly PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anemia In Elderly Market Growth Rate Analysis
• 5.4. Global Anemia In Elderly Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anemia In Elderly Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anemia In Elderly Total Addressable Market (TAM)

6. Anemia In Elderly Market Segmentation

• 6.1. Global Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Injectable
• 6.2. Global Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iron Supplements
• Erythropoietin Or Erythrocyte-Stimulating Agents
• Vitamin B12 Supplements
• Folic Acid Supplements
• 6.3. Global Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Anemia In Elderly Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacy
• Online Pharmacy
• Retail pharmacy
• 6.5. Global Anemia In Elderly Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iron Supplements
• Vitamin B12 Supplements
• Folic Acid Tablets
• Erythropoiesis-Stimulating Agents (ESAs) Tablets
• 6.6. Global Anemia In Elderly Market, Sub-Segmentation Of Injectable, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Iron Injections
• Vitamin B12 Injections
• Erythropoiesis-Stimulating Agents (ESAs) Injections
• Folic Acid Injections

7. Anemia In Elderly Market Regional And Country Analysis

• 7.1. Global Anemia In Elderly Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anemia In Elderly Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anemia In Elderly Market

• 8.1. Asia-Pacific Anemia In Elderly Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anemia In Elderly Market

• 9.1. China Anemia In Elderly Market Overview
• 9.2. China Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anemia In Elderly Market

• 10.1. India Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anemia In Elderly Market

• 11.1. Japan Anemia In Elderly Market Overview
• 11.2. Japan Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anemia In Elderly Market

• 12.1. Australia Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anemia In Elderly Market

• 13.1. Indonesia Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anemia In Elderly Market

• 14.1. South Korea Anemia In Elderly Market Overview
• 14.2. South Korea Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anemia In Elderly Market

• 15.1. Western Europe Anemia In Elderly Market Overview
• 15.2. Western Europe Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anemia In Elderly Market

• 16.1. UK Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anemia In Elderly Market

• 17.1. Germany Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anemia In Elderly Market

• 18.1. France Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anemia In Elderly Market

• 19.1. Italy Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anemia In Elderly Market

• 20.1. Spain Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anemia In Elderly Market

• 21.1. Eastern Europe Anemia In Elderly Market Overview
• 21.2. Eastern Europe Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anemia In Elderly Market

• 22.1. Russia Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anemia In Elderly Market

• 23.1. North America Anemia In Elderly Market Overview
• 23.2. North America Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anemia In Elderly Market

• 24.1. USA Anemia In Elderly Market Overview
• 24.2. USA Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anemia In Elderly Market

• 25.1. Canada Anemia In Elderly Market Overview
• 25.2. Canada Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anemia In Elderly Market

• 26.1. South America Anemia In Elderly Market Overview
• 26.2. South America Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anemia In Elderly Market

• 27.1. Brazil Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anemia In Elderly Market

• 28.1. Middle East Anemia In Elderly Market Overview
• 28.2. Middle East Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anemia In Elderly Market

• 29.1. Africa Anemia In Elderly Market Overview
• 29.2. Africa Anemia In Elderly Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anemia In Elderly Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anemia In Elderly Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anemia In Elderly Market Competitive Landscape And Company Profiles

• 30.1. Anemia In Elderly Market Competitive Landscape
• 30.2. Anemia In Elderly Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Anemia In Elderly Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Amgen Inc
• 31.4. Japan Tobacco Inc
• 31.5. Fresenius Medical Care AG
• 31.6. Teva Pharmaceutical Industries Ltd
• 31.7. Sandoz International GmbH
• 31.8. CSL Limted
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Amag Pharmaceuticals
• 31.11. Akebia Therapeutics Inc
• 31.12. Pharmacosmos A/S
• 31.13. Rockwell Medical Inc
• 31.14. Bioage Labs Inc
• 31.15. Shield Therapeutics Plc

32. Global Anemia In Elderly Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anemia In Elderly Market

34. Recent Developments In The Anemia In Elderly Market

35. Anemia In Elderly Market High Potential Countries, Segments and Strategies

• 35.1 Anemia In Elderly Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anemia In Elderly Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anemia In Elderly Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer